Torren Management
VRDN icon

Torren Management’s Viridian Therapeutics VRDN Stock Holding History

Torren Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$432 Hold
21
– – ﹤0.01% 866
2026
Q2 		$386 Hold
21
– – ﹤0.01% 883
2026
Q1 		$411 Hold
21
– – ﹤0.01% 905
2025
Q4 		$654 Buy
+21
New +$576 ﹤0.01% 1289

Other funds holding VRDN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
J. Safra Sarasin Holding
J. Safra Sarasin Holding $7.05B AUM 26.14% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Torren Management's VRDN Position: Q3 2026 in Review

Torren Management held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 21 shares worth $432. The position accounts for ﹤0.01% of the portfolio, ranked #866.

Torren Management first reported a position in VRDN in Q4 2025 and has held it in 4 quarters since. The position peaked at $654 in Q4 2025. 67 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Torren Management held 21 shares of Viridian Therapeutics worth $432 as of Q3 2026.
  • Torren Management left its Viridian Therapeutics share count unchanged in Q3 2026.
  • Viridian Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q3 2026, its #866 holding.
  • Torren Management first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Torren Management's Viridian Therapeutics position peaked at $654 in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Torren Management's 13F filing for Q3 2026, filed 29 Oct 2026.